SOST and Hypertension: Mendelian randomization studies have reinforced this hypothesis, indicating that higher genetically determined sclerostin levels are associated with a reduced risk of MI, hypertension, DM, coronary artery calcification, coronary artery disease, and worsened cardiovascular biomarkers, including reduced HDL cholesterol and elevated triglyceride levels [31,32].